Documents
Application Sponsors
Marketing Status
Discontinued | 001 |
Discontinued | 002 |
Discontinued | 003 |
Discontinued | 004 |
Discontinued | 005 |
Discontinued | 006 |
Application Products
001 | CAPSULE, EXTENDED RELEASE;ORAL | 1.2MG;10MG | 0 | TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE |
002 | CAPSULE, EXTENDED RELEASE;ORAL | 2.4MG;20MG | 0 | TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE |
003 | CAPSULE, EXTENDED RELEASE;ORAL | 3.6MG;30MG | 0 | TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE |
004 | CAPSULE, EXTENDED RELEASE;ORAL | 4.8MG;40MG | 0 | TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE |
005 | CAPSULE, EXTENDED RELEASE;ORAL | 7.2MG;60MG | 0 | TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE |
006 | CAPSULE, EXTENDED RELEASE;ORAL | 9.6MG;80MG | 0 | TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE |
FDA Submissions
TYPE 3/4; Type 3 - New Dosage Form and Type 4 - New Combination | ORIG | 1 | AP | 2016-08-19 | STANDARD |
LABELING; Labeling | SUPPL | 4 | AP | 2016-12-16 | STANDARD |
REMS; REMS | SUPPL | 5 | AP | 2017-05-26 | N/A |
Submissions Property Types
ORIG | 1 | Null | 6 |
SUPPL | 4 | Null | 15 |
SUPPL | 5 | Null | 15 |
CDER Filings
PFIZER
cder:Array
(
[0] => Array
(
[ApplNo] => 207621
[companyName] => PFIZER
[docInserts] => ["Medication Guide","http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207621s004lbl.pdf#page=32"]
[products] => [{"drugName":"TROXYCA ER","activeIngredients":"NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE","strength":"1.2MG;10MG","dosageForm":"CAPSULE, EXTENDED RELEASE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"},{"drugName":"TROXYCA ER","activeIngredients":"NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE","strength":"2.4MG;20MG","dosageForm":"CAPSULE, EXTENDED RELEASE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"},{"drugName":"TROXYCA ER","activeIngredients":"NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE","strength":"3.6MG;30MG","dosageForm":"CAPSULE, EXTENDED RELEASE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"},{"drugName":"TROXYCA ER","activeIngredients":"NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE","strength":"4.8MG;40MG","dosageForm":"CAPSULE, EXTENDED RELEASE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"},{"drugName":"TROXYCA ER","activeIngredients":"NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE","strength":"7.2MG;60MG","dosageForm":"CAPSULE, EXTENDED RELEASE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"},{"drugName":"TROXYCA ER","activeIngredients":"NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE","strength":"9.6MG;80MG","dosageForm":"CAPSULE, EXTENDED RELEASE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"12\/16\/2016","submission":"SUPPL-4","supplementCategories":"Labeling-Medication Guide","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/207621s004lbl.pdf\"}]","notes":""},{"actionDate":"12\/16\/2016","submission":"SUPPL-4","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/207621s004lbl.pdf\"}]","notes":""},{"actionDate":"08\/19\/2016","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/207621s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"08\/19\/2016","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 3 - New Dosage Form and Type 4 - New Combination","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/207621s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2016\\\/207621Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2016\\\/207621Orig1toc.cfm\"},{\"name\":\"Summary Review (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2016\\\/207621Orig1s000SumR.pdf\"}]","notes":">"}]
[supplements] => [{"actionDate":"05\/26\/2017","submission":"SUPPL-5","supplementCategories":"REMS-Modified","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2017\\\/207621Orig1s005ltr.pdf\"}]","notes":"> Label is not available on this site."},{"actionDate":"12\/16\/2016","submission":"SUPPL-4","supplementCategories":"Labeling-Medication Guide, Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/207621s004lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2016\\\/207621Orig1s004ltr.pdf\"}]","notes":">"},{"actionDate":"09\/30\/2016","submission":"SUPPL-1","supplementCategories":"REMS - MODIFIED - D-N-A","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2016\\\/207621Orig1s001ltr.pdf\"}]","notes":"> Label is not available on this site."}]
[actionDate] => 2017-05-26
)
)